Proveris Scientific expands research team with the addition of accomplished research scientist, Prateek Nath, Ph.D.

Proveris Scientific Corporation, a leading provider of instrumentation and services to advance the science of aerosol and spray products, today announced Prateek Nath has joined as a research scientist in Proveris Scientific’s growing research team.

 

Prateek will perform a range of research activities to advance new technology platforms at Proveris. His focus will be to design and build a wide variety of research-grade prototypes and run experiments on these prototypes to generate proof statements for scientific hypotheses related to aerosol science, human physiology, and drug delivery. In addition, Prateek will actively participate in Proveris’s research collaborations with academic, industrial, and government organizations. 

Prateek holds a Ph.D. in solid mechanics and minors in applied mathematics and materials science from Brown University in Providence, Rhode Island. He earned his Master of Science in mechanical design and optimization from Indian Institute of Technology, Bombay, India, and his Bachelor of Science in mechanical engineering from University of Pune. Prior to joining Proveris, Prateek worked as a computational modeling engineer for Johnson and Johnson in Raynham, Massachusetts, as a research engineer for Bose Corporation in Framingham, Massachusetts, and as a postdoctoral research fellow for Oak Ridge National Laboratory in Oak Ridge, Tennessee. Prateek holds nine U.S. Patents and has authored multiple publications and conference presentations.

Proveris Scientific’s Founder and CEO, Dino Farina, commented, “I’m excited to have Prateek join the Proveris team. Prateek’s significant engineering experience from Oak Ridge National Laboratory, Bose Corporation, and J&J are perfect complements to Proveris’s advanced research focus on integrating human physiology, aerosol science, and drug delivery into better tools for predictive performance modeling of orally inhaled and nasal drug products.”

 

About Proveris Scientific

Proveris Scientific Corporation advances the science of respiratory drug delivery products by driving new technology development for high performance spray characterization, capture, and analysis, while leveraging its expertise, experience, and core technologies. With customer success as its central motivating force, Proveris Scientific adds value to a global customer base with “complete solutions” which include product innovation, technical services, systems, consumables, and educational training. Since its founding in 1995, the company has accelerated the development of top spray and aerosol drug products and has deployed its systems at more than 100 pharmaceutical development and manufacturing sites around the globe. Proveris’s systems are the industry standard and are used by the FDA, CFDA, and the pharmaceutical industry to generate submission-ready data. Proveris is certified to ISO 9001:2015 by TÜV Rheinland of North America, Inc., and has more than 20 patents issued on its technology.

Maria Smith appointed as Director, Application and Business Development for Proveris Laboratories

Proveris Scientific Corporation, a leading provider of instrumentation and services to advance the science of aerosol and spray products, today announced the appointment of Maria L. Smith, M.Sc., to the newly established role of Director, Application and Business Development for Proveris Laboratories. This is a new position focused on addressing the rapid growth of the cGMP contract test services and the introduction of new technologies. 

Maria joins Proveris with more than 14 years of CDMO experience in the development and test of orally inhaled and nasal drug products (OINDPs). She has extensive experience in spray characterization, as well as working with customers on problem resolution and compliance. She has authored 10 publications on spray characterization and is well known across the industry for her professionalism, experience, and expertise.

Maria will help drive the growth of Proveris Laboratories contract test services through the expansion of new applications and technologies. In addition, she will serve as a liaison to regulatory agencies, industry groups, and customers to educate on new technology approaches and how they can be used to support in-vitro in-vivo correlation (IVIVC) and bioequivalence (BE).   

Proveris Scientific’s President, Chip Leveille, commented, “Maria’s fourteen years of laboratory experience in spray/particulate science (nasal and oral products) with leading CDMO’s brings a deep understanding of drug development and testing as it pertains to inhalation products. She has extensive knowledge of Proveris systems and particle characterization techniques to develop and characterize aerosol and spray delivered drug devices. We are excited to have Maria on board to further establish and enhance Proveris technologies as critical approaches to drug approval and product release.”

 

About Proveris Scientific

Proveris Scientific Corporation advances the science of respiratory drug delivery products by driving new technology development for high performance spray characterization, capture, and analysis, while leveraging its expertise, experience, and core technologies. With customer success as its central motivating force, Proveris Scientific adds value to a global customer base with “complete solutions” which include product innovation, technical services, systems, consumables, and educational training. Since its founding in 1995, the company has accelerated the development of top spray and aerosol drug products and has deployed its systems at more than 100 pharmaceutical development and manufacturing sites around the globe. Proveris’s systems are the industry standard and are used by the FDA, CFDA, and the pharmaceutical industry to generate submission-ready data. Proveris is certified to ISO 9001:2015 by TÜV Rheinland of North America, Inc., and has more than 20 patents issued on its technology.

Proveris Laboratories announces expanded services for spray and aerosol characterization of unit-dose nasal drugs

Proveris Scientific Corporation, a leading provider of instrumentation and services to advance the science of aerosol and spray products, today announced the expansion of contract test services for product characterization, performance, safety, and bioequivalence testing of unit-dose nasal drugs.

Utilizing optimized hardware, Proveris Laboratories now offers the ability to perform in vitro characterization testing on unit-dose devices at multiple orientations, allowing developers to test products designed to be administered in a prone position by a physician, first responder, or caregiver. These new service offerings allow developers to not only comply with regulatory guidance, but also gain key insights early in the development process, with regards to device performance.

Proveris Scientific’s other patented technologies and methodologies allow for robust evaluation of unit-dose spray pumps, syringes, pressurized aerosol devices, and both liquid and powder formulations intended for systemic, nose-to-brain, and local delivery. cGMP-compliant and non-GMP test services include predictive modeling experiments using the Proveris by Design™ design of experiments (DoE) method, human actuation studies using Ergo™ technology, and product characterization studies performed on industry gold standard SprayVIEW® Measurement Systems. Vereo® Automated Actuators, which are at the center of most Proveris platforms, are powered by Viota® Software, including unit-dose capability to allow for proper actuation of single shot devices that often require specially tailored profiles to deliver the full dose. 

Alberto Correia, Vice President of Technical Services and Proveris Laboratories commented, “Developers of intranasal branded and generic drugs for the treatment of conditions such as drug overdose reversal and seizures will benefit from Proveris’s simple and precise setup to be able to test their products in multiple orientations, mimicking how these products will actually be administered in real-life situations. Additionally, the unit-dose configuration in our Viota software allows each device to be actuated properly using a force limited methodology ensuring full dose delivery. Force profiles generated from each actuation can help to confirm dose delivery. This is critical for unit dose devices designed for use in combatting life-threatening events such as drug overdose and seizures, as well as for potent drugs where exceeding the dosage limit is dangerous.”

About Proveris Scientific

Proveris Scientific Corporation advances the science of respiratory drug delivery products by driving new technology development for high performance spray characterization, capture, and analysis, while leveraging its expertise, experience, and core technologies. With customer success as its central motivating force, Proveris Scientific adds value to a global customer base with “complete solutions” which include product innovation, technical services, systems, consumables, and educational training. Since its founding in 1995, the company has accelerated the development of top spray and aerosol drug products and has deployed its systems at more than 100 pharmaceutical development and manufacturing sites around the globe. Proveris’s systems are the industry standard and are used by the FDA, CFDA, and the pharmaceutical industry to generate submission-ready data. Proveris is certified to ISO 9001:2015 by TUV Rheinland of North America, Inc., and has more than 20 patents issued on its technology.

DDL 2021

11 – 13 December 2021 | Format TBD

Proveris will sponsor this year’s Drug Delivery to The Lungs conference which will be held 11-13 December. Attendees to our exhibit will be able to explore new tools for spray characterization, studies for predictive in vitro / in vivo correlation, and precision automated actuation technology for through-life testing.

If you would like to learn more and schedule a meeting with us, email us at contactus@proveris.com.

Drug Delivery to the Lungs (DDL) is an annual conference covering all aspects of respiratory drug delivery. It attracts a wide variety of attendees, including scientists, academics, clinicians, regulators and industry experts. It offers a venue for lectures, posters and exhibitions.

IDDA 2021

June 25-27, 2021 | Chengdu, China

Proveris Scientific’s partner in China, Ruty Li of Quantaflux, will attend the Inhalation Drug Delivery Association Conference 2021. He will be at the Proveris table in the exhibit area and will give a presentation entitled, “In vitro Characterization Technology for Soft Mist, Pressurized Metered Dose Inhalers, and Nasal Sprays.”

If you would like to learn more and schedule a meeting with him, email us at contactus@proveris.com.

The Inhalation Drug Delivery Association Conference brings together well-known academics, experts and scholars from China and around the world.  The conference provides a venue for the industry to exchange information, academic views, technologies and interactive communication on applications, laws and regulations, clinical research, market conditions.

RDD 2021

May 4-7, 2021 | Virtual Conference

Proveris is an exhibitor at this year’s Respiratory Drug Delivery Europe (RDD 2021) which will be held online as a virtual conference from 4-7 May. Virtual attendees to our exhibit will be able to explore new tools for spray characterization, studies for predictive in vitro / in vivo correlation, and precision automated actuation technology for through-life testing.

If you would like to learn more and schedule a meeting with us, email us at contactus@proveris.com.

Respiratory Drug Delivery, RDD®, is an international conference for researchers, regulators, business professionals and suppliers active in pulmonary and nasal drug delivery. It provides a venue for expert speakers to cover topics including new therapeutic opportunities, drug delivery technologies, regulatory science and novel in vitro, in vivo and clinical testing methods.

Inhalation China 2021

April 15-16, 2021 | Shanghai, China

Proveris Scientific’s partner in China, Ruty Li of Quantaflux, will attend the 5th Inhalation China Symposium. He will be at the Proveris table in the exhibit area and will give a presentation entitled, “Critical Quality Attributes (CQAs) Comparison Between Soft Mist and Pressurized Metered Dose Inhalers.”

If you would like to learn more and schedule a meeting with him, email us at contactus@proveris.com.

Inhalation China Symposium is organized by Fudan University School of Pharmacy, Pharmaceutical Preparation Committee of Shanghai Pharmaceutical Association, and co-organized by Reed Sino Pharma and Shanghai Pharma. Experts from Central CFDA, Local CFDA, technology companies, R&D organizations, universities, and hospitals speak about current topics related to inhalation drug delivery science, applications, and technology.

Lynn Jordan joins Proveris as Applications Laboratory Manager

Proveris Scientific Corporation, a leading provider of services and technology to advance the science of spray and aerosol products, today announced that experienced life sciences professional Lynn Jordan has joined Proveris as Applications Laboratory Manager.

Lynn joins Proveris with more 25 years of experience in applications and bioanalytical science, laboratory services management, and technical sales at life science technology and instrumentation providers, including:  New England Nuclear, Amicon, Zymark, Waters Corporation, Perkin Elmer, and Biotage. Lynn has a reputation as a strong leader and accomplished scientist with expertise in the introduction of new assays and technologies for sample preparation, analysis, and automation in the life sciences.

In her role at Proveris, Lynn will lead the fulfillment of contract test services, working collaboratively with field sales to meet and exceed technical support standards and customer expectations. Lynn will also play an integral role in product development and R&D projects, adding a customer perspective to the functional specifications. In addition, she will contribute to the development of promotional materials, seminars, and workshop presentations.

Lynn is the author of four publications and contributed to a chapter in “Automated Solid Phase Extraction,” published by Marcel Dekker. Lynn has a bachelor’s degree in Chemistry from Russel Sage College and has completed master’s course work in Separations Sciences from Rensselaer Polytechnical Institute.

 

About Proveris Scientific

Proveris Scientific Corporation advances the science of respiratory drug delivery products by driving new technology development for high performance spray characterization, capture, and analysis, while leveraging its expertise, experience, and core technologies. With customer success as its central motivating force, Proveris Scientific adds value to a global customer base with “complete solutions” which include product innovation, technical services, systems, consumables, and educational training. Since its founding in 1995, the company has accelerated the development of top spray and aerosol drug products and has deployed its systems at more than 100 pharmaceutical development and manufacturing sites around the globe. Proveris’s systems are the industry standard and are used by the pharmaceutical industry to generate submission-ready data and regulatory agencies such as the US FDA and China NMPA (National Medical Products Administration). Proveris is certified to ISO 9001:2015 by TUV Rheinland of North America, Inc., and has more than 20 patents issued on its technology.

Research Collaboration: Next Generation Technologies for Improving the Measurement of Pharmaceutical Aerosols

Proveris Scientific Corporation, a leading provider of instrumentation and services to advance the science of aerosol and spray products, today announced its research collaboration with The University of Sydney and Macquarie University on a project to develop a new generation of measurement technologies for improving the measurement of pharmaceutical aerosols.

The project aims to develop an innovative optical tomography technology capable of direct and real-time measurement of the surface area of airborne particles. By coupling advanced laser diagnostic tools with physiological models and in vitro characterization techniques, the research team will investigate critical relationships between the surface area of an aerosol and its dissolution when delivered to a target. The outcomes will enable aerosol device manufacturers to develop and market more advanced and highly specific products.

The concept, originally conceived by Proveris Scientific, is to significantly enhance the characterization of inhaled aerosols with respect to their potential bioavailability or toxicity. Mr. Dino Farina, Partner Investigator, Proveris Scientific Corporation, Professor Hak-Kim Chan, Chief Investigator from the School of Pharmacy at The University of Sydney, and Dr. Agisilaos Kourmatzis, Chief Investigator from the School of Aerospace, Mechanical, and Mechatronic Engineering at The University of Sydney collaborated on a research plan. The multi-year research collaboration is funded by the Australian Research Council Linkage Program which promotes national and international research partnerships between researchers and business, industry, community organizations, and other publicly funded research agencies. As the administering organizing, Professor Chan and Dr. Kourmatzis also invited Dr. Shaokoon Cheng, Chief Investigator, Macquarie University, as a collaborator on the project.

Dr. Kourmatzis commented, “To me, partnering with Proveris means partnering with an organization who understand that engineering innovation, multidisciplinary research, and the highest quality R&D driven by solid science is what leads to positive changes to people’s lives. As an engineer, I am really excited to work on this project and look forward to a deep engagement which can lead to a long-lasting impact on the aerosols industry.”

Professor Hak-Kim Chan stated, “We are really thrilled to have this excellent opportunity  conducting joint R&D with Proveris in developing a novel technology platform that can shift the paradigm in the field. This project marks the beginning of a long-term relationship with Proveris to maximize mutual beneficial outcomes through strategic collaboration.”

Dr Shaokoon Cheng added, “It is really exciting to work with Proveris in developing a device that could transform how things are currently being measured in the pharmaceutical industries. These engagements are critical to improving the efficiency of work processes that I believe will bring enormous economic benefits to companies.”

Dino Farina concluded, “Significantly enhancing comparative in vivo results utilizing predictive in-vitro technologies for inhaled aerosol characterization is a critical need in providing safer and more efficacious drugs to patients worldwide. Having the ability to work with these three top researchers on this new technology is exciting and will result in technology that will advance inhalation science and help make it a more effective route for drug delivery.”

About Proveris Scientific

Proveris Scientific Corporation advances the science of respiratory drug delivery products by driving new technology development for high performance spray characterization, capture, and analysis, while leveraging its expertise, experience, and core technologies. With customer success as its central motivating force, Proveris Scientific adds value to a global customer base with “complete solutions” which include product innovation, technical services, systems, consumables, and educational training. Since its founding in 1995, the company has accelerated the development of top spray and aerosol drug products and has deployed its systems at more than 100 pharmaceutical development and manufacturing sites around the globe. Proveris’s systems are the industry standard and are used by the FDA, CFDA, and the pharmaceutical industry to generate submission-ready data. Proveris is certified to ISO 9001:2015 by TUV Rheinland of North America, Inc., and has more than 20 patents issued on its technology.

About University of Sydney

The University of Sydney is an Australian public research university in Sydney, Australia. Founded in 1850, it is Australia’s first university and is regarded as one of the world’s leading universities. The university is located in Sydney in the southeastern Australian state of New South Wales. In addition to its main location – the Camperdown/Darlington campus – near the city’s central business district, the university has other campuses and research facilities in Sydney and other areas of Australia. One of the additional sites is the One Tree Island Research Station located near the Great Barrier Reef, which facilitates research on topics such as climate change and geology.

About Macquarie University 

Macquarie University is a public research university based in Sydney, Australia, in the suburb of Macquarie Park. Founded in 1964 by the New South Wales Government, it was the third university to be established in the metropolitan area of Sydney. Established as a verdant university, Macquarie has five faculties, as well as the Macquarie University Hospital and the Macquarie Graduate School of Management, which are located on the university’s main campus in suburban Sydney.

Proveris Scientific welcomes back Joseph Werbeck

Proveris Scientific welcomes back Joseph Werbeck as Senior Director to manage its global technical services organization 

Proveris Scientific Corporation, a leading provider of services and technology to advance the science of spray and aerosol products, today announced that it has expanded its technical services organization with the addition of Senior Director of Technical Service, Joseph Werbeck.

Joe will be responsible for managing the Proveris global Technical Services organization and will report to Vice President, Alberto Correia. Joe previously worked for Proveris from 2014 –2018 as Director of Technical Services.  With this experience he is uniquely qualified to drive service activities for exceptional customer satisfaction in the post-global COVID-19 shutdown period.

Joe has more than 20 years of experience in senior technical service, project management, and field engineering roles gained from his time with industry leaders such as: 908 Devices Inc., Seahorse Bioscience (a division of Agilent Technologies), Bruker Daltonics, and ESI Group.

Joe holds a Bachelor of Science, Management degree from University of Phoenix, Associates in Electronics degree from DeVry University, and a Master’s in Project Management from Boston University.

About Proveris Scientific:

Proveris Scientific Corporation advances the science of respiratory drug delivery products by driving new technology development for high performance spray characterization, capture, and analysis, while leveraging its expertise, experience, and core technologies. With customer success as its central motivating force, Proveris Scientific adds value to a global customer base with “complete solutions” which include product innovation, technical services, systems, consumables, and educational training. Since its founding in 1995, the company has accelerated the development of top spray and aerosol drug products and has deployed its systems at more than 100 pharmaceutical development and manufacturing sites around the globe. Proveris’s systems are the industry standard and are used by the FDA, China NMPA (National Medical Products Administration), and the pharmaceutical industry to generate submission-ready data. Proveris is certified to ISO 9001:2015 by TUV Rheinland of North America, Inc., and has more than 20 patents issued on its technology.